CUE | tickerfilter.com

Fundamental analysis

39%

Profitability 25%

Dept financing 12%

Liquidity 75%

Performance 50%

Company vs Stock growth

2.658 M 3.336 M

678.000 K 25.51%

0.620 1.500

0.880 141.94%

+ Add row to compare

Performance

5 Days

-14.56%

1 Month

-38.63%

3 Months

-57.81%

6 Months

-51.26%

1 Year

-66.91%

2 Year

-80.03%

Key data

Stock price

$0.68

P/E Ratio

0.00

DAY RANGE

$0.66 - $0.81

EPS

-$1.00

52 WEEK RANGE

$0.45 - $2.26

52 WEEK CHANGE

-$66.91

MARKET CAP

36.833 M

YIELD

N/A

SHARES OUTSTANDING

48.643 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.51

PUBLIC FLOAT

AVERAGE 10 VOLUME

$214,346

AVERAGE 30 VOLUME

$141,753

Company detail

CEO: Daniel R. Passeri
Region: US
Website: cuebiopharma.com
Employees: 60
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.

CUE - Cue Biopharma, Inc.